LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep ...
The aura6000 is an implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe ... Comparing median values from baseline to six months with therapy (assessed at ...
As an example, we reached a major milestone in our international expansion with the approval of Nexalin's Gen-2 15 mA neurostimulation device by the Brazilian Health Regulatory Agency (ANVISA) on June ...